All In Biotech

Drug Trial Radar · NCT03093116

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Last checked: Nov 19, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Mar 7, 2017

Primary completion

Feb 29, 2028

Study completion Feb 29, 2028

Sponsor

Sponsor type
Industry
Collaborators
Zai Lab (Shanghai) Co., Ltd.
First posted
Mar 28, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.

Conditions

  • Locally Advanced Solid Tumors
  • Metastatic Solid Tumors

Interventions

  • Oral repotrectinib (TPX-0005)Drug

    Oral repotrectinib (TPX-0005) capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicities (DLTs) (Phase 1)Time frame: Within 28 days of the first repotrectinib dose
  2. Recommended Phase 2 Dose (RP2D) (Phase 1)Time frame: Within 28 days of the last patient dosed in escalation
  3. Overall Response Rate (ORR) Phase 2Time frame: Two to three years after first dose of repotrectinib dose

Locations

165 sites in 19 countries. Site status is shown where the registry gives one.

  • Local Institution - 2129

    Duarte, California · Completed

  • Local Institution - 2120

    Glendale, California · Completed

  • Local Institution - 2136

    La Jolla, California · Withdrawn

  • Local Institution - 2114

    La Jolla, California · Completed

  • Local Institution - 2121

    Long Beach, California · Completed

  • Local Institution - 1001

    Orange, California · Completed

  • Local Institution - 2101

    Orange, California · Completed

  • St Joseph Heritage Healthcare

    Santa Rosa, California · Recruiting

  • Local Institution - 1003

    Aurora, Colorado · Completed

  • Local Institution - 2103

    Aurora, Colorado · Completed

  • Local Institution - 2106

    Washington D.C., District of Columbia · Completed

  • Local Institution - 2110

    Washington D.C., District of Columbia · Completed

  • Memorial Healthcare System

    Hollywood, Florida · Recruiting

  • Local Institution - 2113

    Tampa, Florida · Completed

  • University Cancer and Blood Center

    Athens, Georgia · Recruiting

  • Local Institution - 2134

    Columbus, Georgia · Completed

  • University of Chicago

    Chicago, Illinois · Recruiting

  • Local Institution - 2142

    Peoria, Illinois · Completed

  • Local Institution - 2116

    New Orleans, Louisiana · Not yet recruiting

  • Local Institution - 2133

    Baltimore, Maryland · Completed

  • Massachusetts General Hospital,

    Boston, Massachusetts · Recruiting

  • Local Institution - 1004

    Boston, Massachusetts · Completed

  • Local Institution - 2131

    Boston, Massachusetts · Completed

  • Local Institution - 2105

    Ann Arbor, Michigan · Completed

  • Local Institution - 2111

    Detroit, Michigan · Completed

  • Local Institution - 2140

    Detroit, Michigan · Completed

  • Local Institution - 2132

    Saint Paul, Minnesota · Completed

  • Local Institution - 2147

    Bolivar, Missouri · Completed

  • Washington University Infusion Center Pharmacy

    St Louis, Missouri · Recruiting

  • Local Institution - 2122

    New Brunswick, New Jersey · Completed

  • Local Institution - 2117

    New York, New York · Completed

  • Local Institution - 1002

    New York, New York · Active not recruiting

  • Local Institution - 2102

    New York, New York · Completed

  • Local Institution - 2144

    Goldsboro, North Carolina · Completed

  • Local Institution - 2112

    Canton, Ohio · Completed

  • Local Institution - 2143

    Cincinnati, Ohio · Completed

  • Local Institution - 2109

    Cleveland, Ohio · Completed

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio · Recruiting

  • Local Institution - 2119

    Toledo, Ohio · Completed

  • Local Institution - 2108

    Philadelphia, Pennsylvania · Completed

Showing 40 of 165 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.